278 related articles for article (PubMed ID: 10434578)
1. [Parkinson's disease].
Yokochi M
Ryoikibetsu Shokogun Shirizu; 1999; (27 Pt 2):5-14. PubMed ID: 10434578
[No Abstract] [Full Text] [Related]
2. [Updates in practical neurology--I. The principles of modern levodopa therapy in Parkinson's disease].
Klivényi P; Vécsei L
Ideggyogy Sz; 2007 Jan; 60(1-2):61-4. PubMed ID: 17432097
[TBL] [Abstract][Full Text] [Related]
3. Rehabilitation goals and strategies in Parkinson's disease.
Ceravolo MG
Eur J Phys Rehabil Med; 2009 Jun; 45(2):205-8. PubMed ID: 19532108
[No Abstract] [Full Text] [Related]
4. [Diagnosis and therapy of Parkinson's disease].
Wittstock M; Benecke R
MMW Fortschr Med; 2005 May; 147 Spec No 2():28-31. PubMed ID: 15968869
[TBL] [Abstract][Full Text] [Related]
5. [Pathological gambling behavior in a patient with Parkinson's disease treated with levodopa and bromocriptine].
Montastruc JL; Schmitt L; Bagheri H
Rev Neurol (Paris); 2003 Apr; 159(4):441-3. PubMed ID: 12773874
[TBL] [Abstract][Full Text] [Related]
6. [Hypersexuality during use of levodopa].
van Deelen RA; Rommers MK; Eerenberg JG; Egberts AC
Ned Tijdschr Geneeskd; 2002 Nov; 146(44):2095-8. PubMed ID: 12448966
[TBL] [Abstract][Full Text] [Related]
7. NMDA antagonist memantine improves levodopa-induced dyskinesias and "on-off" phenomena in Parkinson's disease.
Varanese S; Howard J; Di Rocco A
Mov Disord; 2010 Mar; 25(4):508-10. PubMed ID: 20014061
[No Abstract] [Full Text] [Related]
8. [Therapeutic strategies in Parkinson's disease].
Shoulson I
Arch Neurobiol (Madr); 1991; 54(6):277-81. PubMed ID: 1687429
[No Abstract] [Full Text] [Related]
9. [Drug therapy of Parkinson's disease].
Myllylä V
Duodecim; 1997; 113(18):1827-34. PubMed ID: 10892076
[No Abstract] [Full Text] [Related]
10. Therapy of Parkinson's disease: are we at the end of the road?
Nag D
J Assoc Physicians India; 1992 Jun; 40(6):361-3. PubMed ID: 1360470
[No Abstract] [Full Text] [Related]
11. Parkinson's disease.
Clarke C; Moore AP
Clin Evid; 2002 Jun; (7):1208-20. PubMed ID: 12230738
[No Abstract] [Full Text] [Related]
12. Parkinson's disease.
Clarke C; Moore A
Clin Evid; 2002 Dec; (8):1370-85. PubMed ID: 12603943
[No Abstract] [Full Text] [Related]
13. Recent advances in pharmacological therapy of Parkinson's disease.
Riederer P; Lange KW; Youdim MB
Adv Neurol; 1993; 60():626-35. PubMed ID: 8093582
[TBL] [Abstract][Full Text] [Related]
14. Medications for Parkinson's disease.
Whitney CM
Neurologist; 2007 Nov; 13(6):387-8. PubMed ID: 18090719
[No Abstract] [Full Text] [Related]
15. Peak-dose dyskinesia; an acceptable price for mobility in late-stage Parkinson's disease?
Wenzelburger R
Clin Neurophysiol; 2005 Sep; 116(9):1997-8. PubMed ID: 16055380
[No Abstract] [Full Text] [Related]
16. Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements.
Nutt JG
Neurology; 2006 May; 66(10):1611-2; author reply 1611-2. PubMed ID: 16717244
[No Abstract] [Full Text] [Related]
17. [Levodopa for Parkinson's disease: What have we learned?].
Juri C C; Chaná C P
Rev Med Chil; 2006 Jul; 134(7):893-901. PubMed ID: 17130974
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in Parkinson's disease.
Vécsei L
Ideggyogy Sz; 2002 Nov; 55(11-12):406-7. PubMed ID: 12632802
[No Abstract] [Full Text] [Related]
19. Factors influencing dopaminergic therapy of Parkinson's disease.
Horowski R
Funct Neurol; 1988; 3(4):459-70. PubMed ID: 2907501
[No Abstract] [Full Text] [Related]
20. Levodopa for the treatment of Parkinson's disease.
Lewitt PA
N Engl J Med; 2008 Dec; 359(23):2468-76. PubMed ID: 19052127
[No Abstract] [Full Text] [Related]
[Next] [New Search]
